Compare Bristol-Myers Squibb Co (BMY) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Hershey Co — how do they compare? Bristol-Myers Squibb Co trades at $58.51 (market cap $116.30B), while Hershey Co trades at $171.2 (market cap $34.78B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.3× Hershey Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | HSY | |
|---|---|---|
Market Cap | $116.30B | $34.78B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $236.28 |
52-Week Low | $42.60 | $162.31 |
Enterprise Value | $152.24B | $39.58B |
Dividend Yield | 4.42% | 3.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Hershey (HSY) trades at $175.24, up 0.91% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, including Q1 2026 EPS of $2.35 versus $2.04 expected. Revenue growth is steady, with 2025 revenue at $11.69 billion, though net income margin compressed to 9.12% from prior years. Analyst consensus price target is $209.25, implying significant upside, supported by a 3.3% dividend yield and recent margin recovery trends.
The outlook for HSY is cautiously optimistic, with earnings momentum and valuation support offset by near-term technical weakness. Investment opportunity lies in continued execution on margin improvement and innovation, such as new REESE'S PIECES products. Key risks include persistent input cost pressures, competitive threats, and macroeconomic sensitivity. Wall Street sentiment is mixed, with 65.7% hold ratings reflecting balanced risk-reward amid recovery phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
